What is the Purpose of the Study?

The purpose of this study is to evaluate the Ablatherm treatment system for the control of localized prostate cancer in patients who have experienced a local recurrence of their cancer after previous external beam radiation therapy. The study will involve approximately 120 patients in 3-4 medical centers, and the findings will be presented to the Food and Drug Administration (FDA).

Patient Participation : We invite your and/or your physicians' inquiries about our study. It is important that all patient must meet the following criteria in order to be considered for inclusion in this study.

The primary requirements are:

If you feel your condition is consistent with the criteria and you or your doctor would like further information, please contact one of the treatment centers listed below.

How the Therapy Works?

The Ablatherm works by using the ultrasound image to define the shape of the prostate gland and to map the treatment regions. The device then uses high-intensity focused ultrasound (HIFU) technology to heat the targeted areas to therapeutic temperatures.
A coolant is circulated around the treatment probe to ensure a proper energy delivery and to maintain a safe rectal wall temperature.

Study/ Treatment Locations*

Hospital / Urologist

• Georgetown University Medical Center
Dr. John Lynch
Washington, DC
Lombardi Cancer Center
Lombardi CancerLine
Tel: 202 784-4000

• Baylor University Medical Center
Dr. Brian Miles
Houston, TX
http://www.urol.bcm.tmc.edu/
Study Coordinator
Tel: 713 798-8514

• University of California at San Francisco
Dr. Peter Carroll
Dr. Katsuto Shinohara
San Francisco, CA
UCSF Website
Investigator's Office
Tel: 415 353-2200

*NOTE: When calling the above sites, please indicate that you are inquiring about the HIFU prostate cancer study

CAUTION : Under investigation in the US.